A Cincinnati-based biotech startup developing a first-in-class treatment for ALS is celebrating a key regulatory milestone, roughly two years after landing its first tranche of funding from Uptown-based investment firm CincyTech.
Eikonoklastes Therapeutics, a preclinical biotech company developing new drugs for neurodegenerative diseases and cancers, this week received U.S. Food and Drug Administration orphan drug designation for its ET-101 program. According to the FDA, orphan drug designation…
